A Phase 2 Randomized, Controlled, Blinded Study in a Single Center Using Omalizumab With Oral Food Immunotherapy in Children and Adults With Multiple Food Allergies
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2014
Price : $35 *
At a glance
- Drugs Omalizumab (Primary) ; Food allergy immunotherapy
- Indications Food hypersensitivity
- Focus Therapeutic Use
- 25 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 15 Apr 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 12 Mar 2014 New trial record